James Basta Sells 10,397 Shares of Intellia Therapeutics (NASDAQ:NTLA) Stock

by · The Markets Daily

Intellia Therapeutics, Inc. (NASDAQ:NTLA – Get Free Report) EVP James Basta sold 10,397 shares of the stock in a transaction dated Monday, January 5th. The shares were sold at an average price of $9.21, for a total value of $95,756.37. Following the completion of the transaction, the executive vice president directly owned 101,528 shares in the company, valued at $935,072.88. The trade was a 9.29% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Intellia Therapeutics Price Performance

Shares of NTLA stock opened at $10.52 on Friday. The stock has a market cap of $1.22 billion, a PE ratio of -2.46 and a beta of 2.05. The stock has a 50-day moving average of $9.48 and a 200-day moving average of $12.67. Intellia Therapeutics, Inc. has a one year low of $5.90 and a one year high of $28.25.

Intellia Therapeutics (NASDAQ:NTLA – Get Free Report) last released its quarterly earnings data on Thursday, November 6th. The company reported ($0.92) earnings per share for the quarter, topping the consensus estimate of ($1.02) by $0.10. The business had revenue of $13.78 million for the quarter, compared to analyst estimates of $14.12 million. Intellia Therapeutics had a negative net margin of 774.94% and a negative return on equity of 57.01%. Intellia Therapeutics’s quarterly revenue was up 51.6% compared to the same quarter last year. During the same quarter last year, the firm earned ($1.34) EPS. As a group, research analysts anticipate that Intellia Therapeutics, Inc. will post -5.07 earnings per share for the current year.

Wall Street Analysts Forecast Growth

NTLA has been the subject of a number of recent analyst reports. Barclays lowered their price objective on shares of Intellia Therapeutics from $24.00 to $14.00 and set an “overweight” rating for the company in a research report on Friday, November 7th. HC Wainwright lowered their price target on Intellia Therapeutics from $18.00 to $15.00 and set a “buy” rating for the company in a report on Monday, November 10th. William Blair lowered Intellia Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Monday, October 27th. Citigroup reiterated a “market outperform” rating on shares of Intellia Therapeutics in a report on Tuesday, October 28th. Finally, Wedbush decreased their price objective on Intellia Therapeutics from $9.00 to $7.00 and set a “neutral” rating for the company in a research report on Friday, November 7th. Eleven equities research analysts have rated the stock with a Buy rating, ten have given a Hold rating and three have issued a Sell rating to the stock. According to MarketBeat.com, Intellia Therapeutics has a consensus rating of “Hold” and a consensus price target of $18.43.

Get Our Latest Report on NTLA

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of NTLA. Caitong International Asset Management Co. Ltd bought a new stake in Intellia Therapeutics in the 3rd quarter valued at approximately $30,000. Blue Bell Private Wealth Management LLC bought a new position in shares of Intellia Therapeutics during the 3rd quarter worth approximately $30,000. Advisory Services Network LLC acquired a new stake in shares of Intellia Therapeutics in the third quarter valued at approximately $33,000. Headlands Technologies LLC bought a new stake in shares of Intellia Therapeutics in the second quarter worth $26,000. Finally, Danske Bank A S acquired a new position in Intellia Therapeutics during the third quarter worth $50,000. 88.77% of the stock is currently owned by institutional investors.

About Intellia Therapeutics

(Get Free Report)

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.

Featured Stories